(secondQuint)Study Comparing Rifaximin With Xifaxan 200mg in Traveler's Diarrhea.

 This is a randomized, placebo-controlled bioequivalent study with a clinical endpoint in the treatment of travelers' diarrhea.

 After three unformed stools are recorded within the 24 hours immediately preceding randomization, subjects are to be randomized to receive the generic rifaximin 200 mg oral tablet, the reference listed drug (RLD) 200 mg oral tablet or placebo three times daily for 3 days (i.

e.

, on study Days 1, 2, and 3).

 The primary endpoint is clinical cure at the test of cure (TOC) visit on study Day 5.

.

 Study Comparing Rifaximin With Xifaxan 200mg in Traveler's Diarrhea@highlight

The primary objective is to demonstrate rifaximin 200-mg tablets (test) and Xifaxan(R) 200 mg tablets (reference ) are clinically bioequivalent with respect to the clinical cure rates when administered 3 times a day (TID) for 3 days in subjects with travelers' diarrhea.

